`
`Lucentis PFS (RFB002)
`
`Team Members: (= Present, •=part-time)
`
`TRD SubTeam meeting Minutes
`Business Use Only
`
`Meeting Date: Dec. 5, 2011
`Meeting Minutes Date: Dec. 12, 2011
`Author:
`Extended Team Present
`Function
`
`I
`I
`
`I
`
`I
`I
`I
`
`I
`I
`
`I
`
`I
`I
`
`Lucentis CMC Sub Team Meeting Minutes, Meeting Date: Dec. 5, 201 1
`
`1 of 9
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2069.001
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`-
`
`•
`I
`
`I·
`
`I·
`
`I
`I
`I
`
`I
`
`Topic/Situation
`
`Objective/Desired Outcome:
`•
`
`Discussion
`
`I
`
`■•
`
`Lead: -
`
`Pre-reads
`
`Lucentis CMC Sub Team Meeting Minutes. Meeting Date: Dec. 5, 2011
`
`2 of 9
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2069.002
`Regeneron v. Novartis, IPR2021 -00816
`
`
`
`Decisions
`
`I Actions added to action
`
`What
`
`Topic 2:
`
`Topic/Situation
`
`Objective/Desired Outcome:
`
`Actions added to action
`
`Ian
`
`What
`
`When
`
`Lead: -
`
`Pre-reads
`
`None
`
`-
`
`Who -
`-
`
`Topic 3:
`
`I Topic/Situation
`
`Lead; -
`
`Pre-reads
`
`Lucentis CMC Sub Team Meeting Minutes. Meeting Date: Dec. 5, 201 1
`
`3 of 9
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2069.003
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`Objective/Desired Outcome:
`I
`
`Discussion -
`
`None
`
`Decisions
`
`Acti9ns added to action p1an
`
`What
`
`Who
`
`When
`
`Topic/Situation
`
`Objective/Desired Outcome:
`•
`
`Pre-reads
`None
`
`Discussion
`
`I
`I
`
`Decisions
`
`Actions added to action
`
`Ian
`
`What
`
`Who
`
`When
`
`Topic 5:
`
`I Topic/Situation
`
`Lucentis CMC Sub Team Meeting Minutes. Meeting Date: Dec. 5, 201 1
`
`Lea_d:
`
`Pre-reads
`
`4 of 9
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2069.004
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`Objective/Desired Outcome:
`I
`Discussion
`
`None
`
`·I
`I
`
`I
`
`I
`
`De.cisions
`
`Actions added to action Jan
`
`'Topic/Situation
`
`Objective/Desired Outcome:
`I
`
`I
`Discussion
`
`I
`
`Decisions
`
`Actions. added to action. plan
`
`Lead:
`
`Pre-reads
`
`Topic 7:
`Lucentis CMC Sub Team Meeting Minutes. Meeting Date: Dec. 5, 201 1
`
`I Lead: - -
`
`5 of 9
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2069.005
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`Pre~reads
`
`Topic/Situation
`
`Objective/Desired Outcome:
`
`•
`
`Discussion
`
`Decisions
`
`Who
`
`When
`
`- -• --
`
`Lead:.
`
`Pre-reads
`
`Topic 8:
`
`Topic/Situation
`
`Objective/Desired Outcome:
`I
`
`Discussion
`
`I
`
`I
`I
`I
`I
`I
`
`Lucentis CMC Sub Team Meeting Minutes. Meeting Date: Dec. 5, 201 1
`
`6 of 9
`
`CONTAINS CONFIDENTIAL BUSI NESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2069.006
`Regeneron v. Novartis, IPR2021 -00816
`
`
`
`Decisions
`
`Actions added to action
`
`Ian
`
`WhO
`
`-
`
`Pre-reads
`
`Who
`
`Wh.en
`
`Topic 9:
`
`Topic/Situation
`
`Objective/Desired Outcome:
`I
`I
`I
`Discussion
`I
`I
`I
`
`I
`Decisions
`
`Actions
`
`What
`
`Lucentis CMC Sub Team Meeting Minutes. Meeting Date: Dec. 5, 201 1
`
`7 of 9
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2069.007
`Regeneron v. Novartis, IPR2021 -00816
`
`
`
`___.______.___I !
`
`Topic 11: -
`
`Topic/Situation
`
`Objective/Desired Outcome:
`I
`
`I
`
`Discussion
`
`Decisions
`
`Actions added to action
`What
`
`Ian
`
`Lead:.
`
`Pre-reads
`
`None
`
`Who
`
`When
`
`Lucentis CMC Sub Team Meeting Minutes. Meeting Date: Dec. 5, 201 1
`
`8 of 9
`
`CONTAINS CONFIDENTIAL BUSI NESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2069.008
`Regeneron v. Novartis, IPR2021 -00816
`
`
`
`________ _,_,, ; '-re ___________ __,
`
`Lucentis CMC Sub Team Meeting Minutes. Meeting Date: Dec. 5, 201 1
`
`9 of 9
`
`CONTAINS CONFIDENTIAL BUSI NESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2069.009
`Regeneron v. Novartis, IPR2021-00816
`
`